Search

Jeanne S Magram

from Croton on Hudson, NY
Age ~62
Get Report
Also known as:
Jeanne Sue Magram, Jeanne Murphy, Agram N Jeanne
Phone and address:
10 Newton Ct, Croton On Hudson, NY 10520
(914) 329-6173
Connected to:
Selena L Magram, 41Beverly A Magrane, 67Lisa L Magrane, 65Maria E Magrane, 55Mary L Magrane, 69Matthew D Magrane, 29Neide Magrani, 55Amy P Magrann, 71David J Magrann, 69Debra A Magrann, 69

Jeanne Magram Phones & Addresses

  • 10 Newton Ct, Croton Hdsn, NY 10520 (914) 329-6173
  • 1 Newton Ct, Croton on Hudson, NY 10520
  • New York, NY
  • Montclair, NJ
  • 520 Sayre Dr, Princeton, NJ 08540
  • Belchertown, MA
  • San Francisco, CA
  • 10 Newton Ct, Croton Hdsn, NY 10520

Work

Company: Celsius therapeutics Apr 2020 Position: Chief scientific officer

Education

School / High School: University of California, San Francisco 1987 to 1992 Specialities: Biology

Skills

Research

Industries

Biotechnology

Resumes

Resumes

Jeanne Magram Photo 1

Chief Scientific Officer

View page
Location:
Ridgefield, CT
Industry:
Biotechnology
Work:
Celsius Therapeutics
Chief Scientific Officer
Quentis Therapeutics
Chief Scientific Officer
Northern Biologics Aug 1, 2014 - Apr 2018
Chief Scientific Officer
Pfizer Jun 2011 - Jul 2014
Site Head: Centers For Therapeutic Innovation New York
Boehringer Ingelheim Dec 2005 - Jun 2011
Vice President, Immunology and Inflammation
Education:
University of California, San Francisco 1987 - 1992
Columbia University Vagelos College of Physicians and Surgeons 1983 - 1987
Doctorates, Doctor of Philosophy, Biology Rutgers University 1979 - 1983
Bachelors, Bachelor of Arts, Chemistry East Brunswick High School
Columbia University
Doctorates, Doctor of Philosophy
Skills:
Research

Publications

Us Patents

Fgf23 Fusion Proteins

View page
US Patent:
20170226172, Aug 10, 2017
Filed:
Mar 30, 2015
Appl. No.:
15/300048
Inventors:
- New York NY, US
Jeanne Sue MAGRAM - Croton-on-Hudson NY, US
Kristen Leigh JOHNSON - New York NY, US
International Classification:
C07K 14/50
Abstract:
Disclosed herein are FGF23 c-tail fusion proteins, pharmaceutical compositions comprising the FGF23 c-tail fusion proteins, and methods of treatment using the FGF23 c-tail fusion proteins. This application discloses fusion proteins comprising a FGF-23 c-tail protein fused to a heterologous amino acid sequence, wherein said fusion protein modulates serum phosphate levels but does not substantially modulate serum 1, 25 VitD levels. In some embodiments, the FGF-23 c-tail protein is fused to the heterologous amino acid sequence via a linker. This invention also encompasses vectors comprising the nucleic acids disclosed herein, and a host cell comprising the vector or polynucleotides encoding the proteins of the invention.

Effectors Of Par-2 Activation And Their Use In The Modulation Of Inflammation

View page
US Patent:
20110311553, Dec 22, 2011
Filed:
Jun 15, 2011
Appl. No.:
13/160758
Inventors:
Tobias LITZENBURGER - Mittelbiberach, DE
Sandra MILLER - Munich, DE
Catrin PRACHT - Neuried, DE
Rainer BOXHAMMER - Munich, DE
Jeanne MAGRAM - Croton-on-Hudson NY, US
Patricia GIBLIN - Brookfield CT, US
Daniel RAJOTTE - Lorraine, CA
Assignee:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH - Ingelheim am Rhein
International Classification:
A61K 39/395
A61P 29/00
A61P 11/06
A61P 19/02
A61P 17/00
A61P 1/00
C07K 16/28
A61P 17/06
US Classification:
4241721, 5303891
Abstract:
The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.

Effectors Of Par-2 Activation And Their Use In The Modulation Of Inflammation

View page
US Patent:
20100119506, May 13, 2010
Filed:
Jul 30, 2009
Appl. No.:
12/512251
Inventors:
Tobias LITZENBURGER - Newtown CT, US
Sandra MILLER - Muenchen, DE
Catrin PRACHT - Neuried, DE
Rainer BOXHAMMER - Muenchen, DE
Jeanne MAGRAM - Croton-on-Hudson NY, US
Patricia GIBLIN - Brookfield CT, US
Daniel RAJOTTE - Lorraine, CA
Assignee:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH - Ingelheim
International Classification:
A61K 39/395
C07K 16/00
A61P 37/06
US Classification:
4241331, 5303871, 5303873, 4241301
Abstract:
The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.
Control profile
Jeanne S Magram from Croton on Hudson, NY, age ~62 Get Report